Latest news with #ESCC
BBC News
4 days ago
- Business
- BBC News
Eastbourne day centre saved after council U-turn on closure
East Sussex County Council has backtracked on plans to close a day centre for adults with autism and learning council previously said it had "reluctantly" looked at shutting Linden Court, in Eastbourne, as demand outstripped available on Tuesday, councillors agreed to reduce the capacity from 45 places each day to 25, which "meets its current usage", instead of closing the council said the reduction in places saved £145,000 but it now needed to make £182,000 of cuts elsewhere instead. There are currently 44 people regularly attending the day service, with around 60% of available spaces filled. Evening sessions have a lower attendance, about 10%.The service had been marked for closure but it was feared that could lead to some clients moving into full-time residential care, the Local Democracy Reporting Service officers highlighted in a report that the average cost of residential care for a high-needs individual would come to about £75, said it meant that even if just three clients moved into residential care, it would reduce the overall £327,000 saving by around £225, light of this, the council has chosen to keep the service running, but with a reduced had previously declared it was in its "worst financial situation ever" and needed to cut nearly £4m from its adult social care budget for 2025/26.
&w=3840&q=100)
Business Standard
25-06-2025
- Business
- Business Standard
Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra
Glenmark Pharmaceuticals share price today: Pharmaceutical major Glenmark Pharmaceuticals shares rose as much as 2.74 per cent to hit an intraday high of ₹1,728 per share on Wednesday, June 25, 2025. Around 1:05 PM, Glenmark Pharmaceuticals shares continued to trade higher, up 1.82 per cent at ₹1,712.50 per share. In comparison, BSE Sensex was trading 0.71 per cent higher at 82,636.70 levels. Why did Glenmark Pharmaceuticals share price rise today? Glenmark Pharmaceuticals share price gained in trade after the company announced the launch of Tevimbra (tislelizumab) in India, following approval by the Central Drugs Standard Control Organisation (CDSCO). Tevimbra is a uniquely engineered anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology innovator focused on delivering cutting-edge cancer therapies. The drug is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy, and as a second-line monotherapy for both locally advanced/metastatic NSCLC and esophageal squamous cell carcinoma (ESCC). The launch marks Glenmark Pharmaceuticals' entry into the immuno-oncology space in India and is a key step in broadening its oncology portfolio with innovative therapies. NSCLC accounts for over 80 per cent of all lung cancer cases, while ESCC is the most prevalent histological subtype of esophageal cancer in India. Tevimbra addresses the major treatment needs of this large patient base with a differentiated and evidence-backed option, the company said. Already approved and available in major markets including the US, EU, Australia, and China, Tevimbra is designed to selectively bind to PD-1 receptors, restoring T-cell function and limiting off-target immune suppression. It has shown strong efficacy and a favourable safety profile across various solid tumors in multiple Phase 3 studies and a global clinical programme. Glenamark Pharmaceuticals Q4 results For the fourth quarter of FY2024-25 (Q4FY25), Glenmark Pharmaceuticals reported a consolidated revenue of ₹3,256.2 crore, marking a year-on-year (Y-o-Y) growth of 6.3 per cent from ₹3,063 crore in the same period last year. The company's Ebitda for the quarter stood at ₹560.7 crore, up 11.2 per cent from ₹504.3 crore, with an Ebitda margin of 17.2 per cent. Adjusted Profit After Tax (PAT) for the quarter came in at ₹346.6 crore, reflecting an adjusted PAT margin of 10.6 per cent. For the full fiscal year ended March 31, 2025 (FY25), the company's consolidated revenue rose 12.8 per cent to ₹13,321.7 crore, compared to ₹11,813.1 crore in the previous year. Ebitda for FY25 more than doubled to ₹2,351 crore from ₹1,195.3 crore, with the Ebitda margin improving to 17.6 per cent. The company also posted an adjusted PAT of ₹1,389.4 crore for the year, resulting in an adjusted PAT margin of 10.4 per cent. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-driven global pharmaceutical company with a strong presence across Branded, Generics, and OTC segments. The company focuses on key therapeutic areas including respiratory, dermatology, and oncology. With 11 state-of-the-art manufacturing facilities spread across four continents and operations in over 80 countries, Glenmark Pharmaceuticals has established itself as a major player in the global pharmaceutical landscape. The market capitalisation of Glenmark Pharmaceuticals is ₹48,171.68 crore, according to BSE. The company falls under the BSE 500 index. Glenmark Pharmaceuticals' 52-week high is ₹1,830.05 per share, while its 52-week low is ₹1,199.95 apiece.
&w=3840&q=100)
Business Standard
24-06-2025
- Business
- Business Standard
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard
24-06-2025
- Business
- Business Standard
Glenmark Pharma launches TEVIMBRA in India
Glenmark Pharmaceuticals announced that it had launched TEVIMBRA (tislelizumab) in India after receiving approval from the Central Drugs Standard Control Organization (CDSCO). The drug is a specially designed anti-PD-1 monoclonal antibody created by BeiGene, now BeOne Medicines, which focuses on oncology. TEVIMBRA is intended for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) when combined with chemotherapy. It is also approved for second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as a standalone therapy. The launch signifies Glenmark's entry into the immuno-oncology market in India. This strategic step aims to expand its innovative oncology offerings. NSCLC represents more than 80% of lung cancer cases, while ESCC is the most common type of esophageal cancer in India. TEVIMBRA is already approved and available in major markets such as the US, the EU, Australia, and China. The therapy specifically targets PD-1 receptors, helping to restore T-cell function while reducing off-target immune suppression. It has shown strong effectiveness and a good safety profile in several key Phase 3 trials across a variety of solid tumors. Alok Malik, President and Business Head India Formulations, Glenmark Pharmaceuticals, said, At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access TEVIMBRA, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers that are difficult to treat. Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across branded, generic, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported a net profit of Rs 4.65 crore in Q4 March 2025 as against a net loss of Rs 1,218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025. Shares of Glenmark Pharmaceuticals rose 0.78% to Rs 1,699.25 on the BSE.
Business Standard
24-06-2025
- Health
- Business Standard
Glenmark Pharmaceuticals launches TEVIMBRA in India
Glenmark Pharmaceuticals (Glenmark) launched TEVIMBRA (tislelizumab) in India following the approval by Central Drugs Standard Control Organization (CDSCO). TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. It is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and esophageal squamous cell carcinoma (ESCC) as monotherapy. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio. NSCLC is the most common type of lung cancer, representing over 80% of all lung cancer cases. Similarly, ESCC is the most common histological subtype of esophageal cancer in India. TEVIMBRA caters to the needs of this significant patient population by offering a differentiated and proven treatment option for these cancers. TEVIMBRA is approved and marketed in multiple leading global markets including the United States, European Union, Australia and China. Designed to selectively bind to PD-1 receptors, TEVIMBRA restores T-cell function while minimizing off-target immune suppression and has demonstrated robust efficacy with a favorable safety profile across diverse solid tumor types in multiple pivotal Phase 3 studies and through a comprehensive global clinical development program.
